Prof. Giuseppe Tonini

Campus Bio-Medico University of Rome, Italy

Email: g.tonini@unicampus.it

Qualifications

2001 Ph.D., “Tor Vergata” University, Thoracic Oncology

Publications (Selected)

1. Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015 Nov;28(11):1481-91.
2. Vincenzi B, Nannini M, Fumagalli E, Bronte G, Frezza AM, De Lisi D, Spalato Ceruso M, Santini D, Badalamenti G, Pantaleo MA, Russo A, Dei Tos AP, Casali P, Tonini G. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Oncotarget. 2015 Sep 24. [Epub ahead of print] PubMed PMID: 26416414.
3. Vincenzi B, Cremolini C, Sartore-Bianchi A, Russo A, Mannavola F, Perrone G, Pantano F, Loupakis F, Rossini D, Ongaro E, Bonazzina E, Dell'Aquila E, Imperatori M, Zoccoli A, Bronte G, De Maglio G, Fontanini G, Natoli C, Falcone A, Santini D, Onetti-Muda A, Siena S, Tonini G, Aprile G. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget. 2015 Oct 13;6(31):31604-12.
4. Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol.2015 Oct;16(13):1306-15.
5. Santini D, Stumbo L, Spoto C, D'Onofrio L, Pantano F, Iuliani M, Fioramonti M, Zoccoli A, Ribelli G, Virzì V, Vincenzi B, Tonini G. Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence.Breast Cancer Res. 2015 Sep 2;17(1):121.
6. Pezzuto A, Stumbo L, Russano M, Crucitti P, Scarlata S, Caricato M, Tonini G. "Impact of Smoking Cessation Treatment" on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study. Recent Pat Anticancer Drug Discov. 2015;10(3):342-51.
7. Vincenzi B, Stumbo L, Maltese G, Cerbone L, Spalato Ceruso M, Badalamenti G, Santini D, Tonini G, Frezza AM, De Lisi D, Silletta M. Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study. Sci Rep. 2015 Aug 3;5:12077.
8. Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G. Prognostic Relevance of Objective Response According to EASL Criteria and Mrecist Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS One. 2015 Jul 31;10(7):e0133488.
9. Pantano F, Iuliani M, Zoccoli A, Fioramonti M, De Lisi D, Fioroni I, Ribelli G, Santoni M, Vincenzi B, Tonini G, Santini D. Emerging drugs for the treatment of bone metastasis. Expert Opin Emerg Drugs. 2015 Jun 25:1-15.
10. Vincenzi B, Imperatori M, Picardi A, Vespasiani Gentilucci U, Gallo P, Fausti V, Spalato Ceruso M, Santini D, Tonini G. Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience. Expert Rev Anticancer Ther. 2015 Aug;15(8):971-6.
11. Cazzato RL, Buy X, Grasso RF, Luppi G, Faiella E, Quattrocchi CC, Pantano F, Beomonte Zobel B, Tonini G, Santini D, Palussiere J. Interventional Radiologist's perspective on the management of bone metastatic disease. Eur J Surg Oncol. 2015 Aug;41(8):967-74.
12. Santoni M, Conti A, Andrikou K, Bittoni A, Lanese A, Pistelli M, Pantano F, Vincenzi B, Armento G, Massari F, Tonini G, Cascinu S, Santini D. Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. Crit Rev Oncol Hematol. 2015 Jun 9. pii: S1040-8428(15)00096-7.
13. Russano M, Vincenzi B, Venditti O, D'Onofrio L, Ratta R, Guida FM, Tonini G, Santini D. Pazopanib and pancreatic toxicity: a case report. BMC Res Notes. 2015 May 14;8:196.
14. Berardi R, Rinaldi S, Santini D, Vincenzi B, Giampieri R, Maccaroni E, Marcucci F, Francoletti M, Onofri A, Lucarelli A, Pierantoni C, Tonini G, Cascinu S. Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. Support Care Cancer. 2015 May;23(5):1295-302.
15. Vincenzi B, Imperatori M, Silletta M, Marrucci E, Santini D, Tonini G. Emerging kinase inhibitors of the treatment of gastric cancer. Expert Opin Emerg Drugs. 2015 May 28:1-15.
16. Iuliani M, Pantano F, Buttigliero C, Fioramonti M, Bertaglia V, Vincenzi B, Zoccoli A, Ribelli G, Tucci M, Vignani F, Berruti A, Scagliotti GV, Tonini G, Santini D. Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget. 2015 May 20;6(14):12520-8.
17. Tonini G. Trends in the early investigational drug development and areas for improvement. Expert Opin Investig Drugs. 2015 Jul;24(7):845-50.
18. Pantano F, Santoni M, Procopio G, Rizzo M, Iacovelli R, Porta C, Conti A, Lugini A, Milella M, Galli L, Ortega C, Guida FM, Silletta M, Schinzari G, Verzoni E, Modica D, Crucitti P, Rauco A, Felici A, Ballatore V, Cascinu S, Tonini G, Carteni G, Russo A, Santini D. The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker? PLoS One. 2015 Apr 17;10(4):e0120427.
19. Vincenzi B, Iuliani M, Zoccoli A, Pantano F, Fioramonti M, De Lisi D, Frezza AM, Rabitti C, Perrone G, Onetti Muda A, Russo A, Giordano A, Santini D, Dei Tos AP, Tonini G. Deregulation of dicer and mir-155 expression in liposarcoma. Oncotarget. 2015 Apr 30;6(12):10586-91.
20. Vincenzi B, D'Onofrio L, Frezza AM, Grasso RF, Fausti V, Santini D, Dei Tos AP, Tonini G. Classic Kaposi Sarcoma: to treat or not to treat? BMC Res Notes. 2015 Apr 10;8:138.
21. Venditti O, De Lisi D, Caricato M, Caputo D, Capolupo GT, Taffon C, Pagliara E, Battisi S, Frezza AM, Onetti Muda A, Tonini G, Santini D. Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis. BMC Cancer. 2015 Mar 1;15:87.
22. Fioroni I, Dell'Aquila E, Pantano F, Intagliata S, Caricato M, Vincenzi B, Coppola R, Santini D, Tonini G. Role of c-mesenchymal-epithelial transitino pathway in gastric cancer. Expert Opin Pharmacother. 2015 Jun;16(8):1195-207.
23. Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F; CAPRI-GOIM investigators. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol. 2015 Aug;26(8):1710-4.
24. Cazzato RL, Palussière J, Buy X, Denaro V, Santini D, Tonini G, Grasso RF, Zobel BB, Poretti D, Pedicini V, Balzarini L, Lanza E. Percutaneous Long Bone Cementoplasty for Palliation of Malignant Lesions of the Limbs: A Systematic Review. Cardiovasc Intervent Radiol. 2015 Mar 24.
25. Cremolini C, Loupakis F, Antoniotti C, Lonardi S, Masi G, Salvatore L, Cortesi E, Tomasello G, Spadi R, Zaniboni A, Tonini G, Barone C, Vitello S, Longarini R, Bonetti A, D'Amico M, Di Donato S, Granetto C, Boni L, Falcone A. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol. 2015 Jun;26(6):1188-94.